A NOVEL ANTIBODY FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA

Search for this publication on Google Scholar
Wu, S. (2017). A NOVEL ANTIBODY FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA. Unc Charlotte Electronic Theses And Dissertations.
Download PDF

Analytics

168 views ◎
100 downloads ⇓


Abstract

Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancer with a 5-year survival rate below 10%. Two of the major contributors to this dismal prognosis are late-stage diagnosis and limited treatment options. Common symptoms of PDA like weight loss, abdominal pains, and jaundice do not appear until the cancer has progressed to late stage and the tumor is of significant size. Surgery and systemic delivery of chemotherapies is the standard treatment for patients, but the associated side effects are severe and the overall survival rate remains unchanged. Therefore early detection (Chapter 2) and targeted drug delivery (Chapter 3) in PDA is highly desirable. Mucin 1 (MUC1) is a tumor-associated antigen (tMUC1) expressed on 80% of human PDA. Here I report the targeting capabilities of TAB004, a tMUC1 specific antibody, for diagnosing and treatment purposes using a fluorophore bound antibody and a TAB004-conjugated PEGylated PLGA (poly lactic-co-glycolic acid) nanoparticle that is loaded with a paclitaxel (PTX). In orthotopic immunocompetent mice, I show that TAB004 specifically targets the tumor without significant accumulation in other organs. Conjugating TAB004 to the surface of PLGA Nanoparticles (T-NPs) significantly increased their internalization into PDA cells as well as their cytolysis of PDA cells when compared to the non-conjugated PLGA-NPs. In vivo, the T-NPs showed dramatically increased accumulation within the pancreatic tumor when compared to the non-conjugated PLGA NPs. The data suggests that TAB004 is a promising antibody to deliver imaging agents and treatments directly to the pancreatic tumor microenvironment, thus improving detection and treatment of PDA.

Details
Author

Wu, Shuta

Title

A NOVEL ANTIBODY FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA

Physical Description

1 online resource (106 pages) : PDF

Date

2017

Degree Granting Institution

University of North Carolina at Charlotte

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancer with a 5-year survival rate below 10%. Two of the major contributors to this dismal prognosis are late-stage diagnosis and limited treatment options. Common symptoms of PDA like weight loss, abdominal pains, and jaundice do not appear until the cancer has progressed to late stage and the tumor is of significant size. Surgery and systemic delivery of chemotherapies is the standard treatment for patients, but the associated side effects are severe and the overall survival rate remains unchanged. Therefore early detection (Chapter 2) and targeted drug delivery (Chapter 3) in PDA is highly desirable. Mucin 1 (MUC1) is a tumor-associated antigen (tMUC1) expressed on 80% of human PDA. Here I report the targeting capabilities of TAB004, a tMUC1 specific antibody, for diagnosing and treatment purposes using a fluorophore bound antibody and a TAB004-conjugated PEGylated PLGA (poly lactic-co-glycolic acid) nanoparticle that is loaded with a paclitaxel (PTX). In orthotopic immunocompetent mice, I show that TAB004 specifically targets the tumor without significant accumulation in other organs. Conjugating TAB004 to the surface of PLGA Nanoparticles (T-NPs) significantly increased their internalization into PDA cells as well as their cytolysis of PDA cells when compared to the non-conjugated PLGA-NPs. In vivo, the T-NPs showed dramatically increased accumulation within the pancreatic tumor when compared to the non-conjugated PLGA NPs. The data suggests that TAB004 is a promising antibody to deliver imaging agents and treatments directly to the pancreatic tumor microenvironment, thus improving detection and treatment of PDA.

Genre

doctoral dissertations

Subjects--Topics

Biology
Oncology

Degree

Ph.D.

Keywords

MUCL
Mucin 1
Nanoparticles
Pancreatic Cancer
PLGA
Targeted Therapy

Subject Area

Biology

Advisor(s)

Mukherjee, Pinku

Committee Members

Dreau, Didier
Ogle, Craig
Richardson, Christine
Yan, Shan

Degree Note

Thesis (Ph.D.)--University of North Carolina at Charlotte, 2017.

Rights Statement

This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). For additional information, see http://rightsstatements.org/page/InC/1.0/.

Rights Holder Information

Copyright is held by the author unless otherwise indicated.

Identifier

Wu_uncc_0694D_11527

Permalink

http://hdl.handle.net/20.500.13093/etd:491